Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNASDAQ:NARINASDAQ:NVCRNYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$96.62+1.2%$102.37$77.91▼$163.71$5.47B0.88646,054 shs545,203 shsNARIInari Medical$79.97$79.97$37.23▼$79.99$4.68B1.021.32 million shsN/ANVCRNovoCure$18.50-0.3%$18.48$12.17▼$34.13$2.06B0.651.19 million shs1.01 million shsSTVNStevanato Group€21.46-2.0%€20.76€16.56▼€28.77$6.54B0.52344,012 shs218,200 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos+1.49%+7.17%-6.43%-39.80%-4.37%NARIInari Medical0.00%0.00%0.00%+0.29%+109.46%NVCRNovoCure-0.27%+18.74%+0.33%-29.74%+49.92%STVNStevanato Group-1.83%-1.92%+2.19%+0.33%-21.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.6465 of 5 stars4.54.00.04.42.12.50.6NARIInari Medical0.6046 of 5 stars1.10.00.00.02.52.50.6NVCRNovoCure3.6763 of 5 stars3.33.00.04.51.81.70.0STVNStevanato Group0.8583 of 5 stars0.01.01.70.02.10.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.92Moderate Buy$156.1761.63% UpsideNARIInari Medical 2.14Hold$68.00-14.97% DownsideNVCRNovoCure 2.67Moderate Buy$32.8377.48% UpsideSTVNStevanato Group 2.86Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest NVCR, STVN, GKOS, and NARI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/21/2025STVNStevanato GroupStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/16/2025GKOSGlaukosMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$200.00 ➝ $175.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/15/2025GKOSGlaukosPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$180.00 ➝ $165.004/11/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$185.00 ➝ $140.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.003/7/2025STVNStevanato GroupWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/7/2025STVNStevanato GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$24.00 ➝ $23.502/21/2025GKOSGlaukosWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$153.00 ➝ $160.002/21/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$149.00 ➝ $176.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$383.48M14.25N/AN/A$9.46 per share10.21NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91NVCRNovoCure$605.22M3.41N/AN/A$3.39 per share5.46STVNStevanato Group$1.10B5.89€0.90 per share23.97€4.15 per share5.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$134.66M-$2.87N/AN/AN/A-39.04%-16.53%-10.61%4/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%4/28/2025 (Estimated)NVCRNovoCure-$207.04M-$1.56N/AN/AN/A-25.93%-41.48%-12.74%N/ASTVNStevanato Group$157.62M€0.4845.6637.007.1810.47%9.86%5.79%N/ALatest NVCR, STVN, GKOS, and NARI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025GKOSGlaukos-$0.33N/AN/AN/A$102.78 millionN/A4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million3/6/2025Q4 2024STVNStevanato Group€0.20€0.20N/A€0.19€346.26 million€352.68 million2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 million2/20/2025Q4 2024GKOSGlaukos-$0.38-$0.40-$0.02-$0.60$100.72 million$105.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ASTVNStevanato Group€0.060.28%N/A12.50%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.195.544.71NARIInari MedicalN/A1.771.40NVCRNovoCure0.271.491.44STVNStevanato Group0.221.811.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%NARIInari Medical90.98%NVCRNovoCure84.61%STVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipGKOSGlaukos6.40%NARIInari Medical10.60%NVCRNovoCure6.29%STVNStevanato Group0.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78056.57 million51.61 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableSTVNStevanato Group4,650302.84 million300.72 millionOptionableNVCR, STVN, GKOS, and NARI HeadlinesRecent News About These CompaniesStevanato Group (NYSE:STVN) Upgraded at StephensApril 25 at 6:28 AM | marketbeat.comStevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025April 24 at 6:14 PM | businesswire.comStevanato Group resumed with an Overweight at StephensApril 22, 2025 | markets.businessinsider.comS&P 500 Futures Fall in Premarket Trading; Kimco Realty, Stevanato Group LagApril 21, 2025 | marketwatch.comStevanato Group (NYSE:STVN) Shares Gap Down - Here's WhyApril 19, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Given Average Rating of "Moderate Buy" by BrokeragesApril 18, 2025 | marketbeat.comLPL Financial LLC Purchases 16,915 Shares of Stevanato Group S.p.A. (NYSE:STVN)April 17, 2025 | marketbeat.comComgest Global Investors S.A.S. Sells 106,010 Shares of Stevanato Group S.p.A. (NYSE:STVN)April 16, 2025 | marketbeat.comGrandeur Peak Global Advisors LLC Lowers Holdings in Stevanato Group S.p.A. (NYSE:STVN)April 14, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Shares Sold by Wellington Management Group LLPApril 13, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Shares Sold by CenterBook Partners LPApril 12, 2025 | marketbeat.comWilliam Blair Remains a Buy on Stevanato Group (STVN)April 11, 2025 | markets.businessinsider.com593,860 Shares in Stevanato Group S.p.A. (NYSE:STVN) Purchased by Ranger Investment Management L.P.April 11, 2025 | marketbeat.comMorgan Stanley Sticks to Their Hold Rating for Stevanato Group (STVN)April 8, 2025 | markets.businessinsider.comStevanato Group (NYSE:STVN) Reaches New 12-Month Low - Time to Sell?April 6, 2025 | marketbeat.comCinctive Capital Management LP Acquires 58,792 Shares of Stevanato Group S.p.A. (NYSE:STVN)April 6, 2025 | marketbeat.comSei Investments Co. Lowers Stock Position in Stevanato Group S.p.A. (NYSE:STVN)April 4, 2025 | marketbeat.comPictet Asset Management Holding SA Sells 12,172 Shares of Stevanato Group S.p.A. (NYSE:STVN)April 3, 2025 | marketbeat.com34,690 Shares in Stevanato Group S.p.A. (NYSE:STVN) Acquired by Allianz SEApril 1, 2025 | marketbeat.comArtisan Partners Limited Partnership Acquires 524,989 Shares of Stevanato Group S.p.A. (NYSE:STVN)March 30, 2025 | marketbeat.comFox Run Management L.L.C. Acquires Shares of 14,544 Stevanato Group S.p.A. (NYSE:STVN)March 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCR, STVN, GKOS, and NARI Company DescriptionsGlaukos NYSE:GKOS$96.62 +1.19 (+1.25%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$96.64 +0.02 (+0.02%) As of 04/25/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.NovoCure NASDAQ:NVCR$18.50 -0.05 (-0.27%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$18.67 +0.17 (+0.92%) As of 04/25/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Stevanato Group NYSE:STVN€21.46 -0.43 (-1.96%) As of 04/25/2025 03:59 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
